“AI is not Taking the Lead, AI is the Enabler” - With David Caumartin

How RebrAIn Is Redefining Neurosurgery with AI: An Interview with CEO David Caumartin

Artificial Intelligence is no longer a buzzword in MedTech - it’s a powerful enabler. In our latest episode of The Crux of MedTech, we sat down with David Caumartin, CEO of RebrAIn, to explore how their supervised, explainable AI is disrupting one of the most complex procedures in medicine: neurosurgery.

With a track record spanning 30 years in global medtech - at GE Healthcare, Theraclion, and now RebrAIn - David brings a deep understanding of what it takes to turn cutting-edge ideas into scalable impact.

From Six-Hour Brain Surgery to Two

RebrAIn’s core innovation? Using explainable AI trained on less than 100 high-quality cases to achieve sub-millimetre accuracy in Deep Brain Stimulation (DBS) and lesioning for conditions like Parkinson’s disease and essential tremor.

Traditional DBS procedures take 6–8 hours and require a full surgical team. RebrAIn’s solution cuts that time to under 2 hours, with comparable or better outcomes - without compromising safety or precision. It’s AI as an assistant, not a replacement - enhancing surgeon confidence while improving patient access and outcomes.

Why This Matters: The Hidden Crisis in Neuro Care

Only about 1% of patients who could benefit from DBS or HIFU (High Intensity Focused Ultrasound) actually receive treatment. Barriers include procedural complexity, limited neurosurgeon capacity, and high costs.

RebrAIn tackles all three.

• It’s scalable: AI allows junior surgeons to deliver outcomes previously dependent on decades of experience.

• It’s accessible: The system runs on a simple SaaS model - no hardware overhaul needed.

• It’s safe: Clinical studies show non-inferiority in blinded, multicentre trials across Parkinson’s and tremor treatment.

And the implications go beyond DBS and HIFU.

What’s Next: From Brain Surgery to Brain Modulation

David shared his vision for the future: extending the technology into Low-Intensity Focused Ultrasound (LoFU) - a non-invasive method for modulating brain circuits without making a single incision. Early trials are exploring its use in depression, epilepsy, and addiction - conditions that currently carry a massive cost burden for healthcare systems worldwide.

As RebrAIn prepares for its €10M Series A, the aim is clear: move from early commercialisation to wide-scale adoption across 300+ global sites by 2029.

Final Thoughts: Software Is Eating MedTech

RebrAIn doesn’t make implants. It doesn’t build capital equipment. Instead, it turns good data into great decisions. And as David put it, “AI is not replacing surgeons. But there will be no surgeon without AI in the future.”

With CE and FDA clearance, clinical validation, and growing surgeon enthusiasm - RebrAIn is positioning itself not just as a software tool, but as the neural operating system of the next decade in functional neurosurgery.